RegeneRx said that based on encouraging "compassionate use" data showing RGN-259's potential healing effects in patients with non-healing corneal ulcers, the company will close its current Phase II clinical trial targeting a small subset of diabetic patients undergoing vitrectomy surgery in order to focus on a patient population with broader market potential. RegeneRx release